Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Med Chem
2012 Sep 13;5517:7841-8. doi: 10.1021/jm3008954.
Show Gene links
Show Anatomy links
Crystal structure of human aurora B in complex with INCENP and VX-680.
Elkins JM
,
Santaguida S
,
Musacchio A
,
Knapp S
.
Abstract
We present the structure of the human Aurora B kinase domain in complex with the C-terminal Aurora-binding region of human INCENP and the Aurora kinase inhibitor VX-680. The structure unexpectedly reveals a dimeric arrangement of the Aurora B:INCENP complex, which was confirmed to exist in solution by analytical ultracentrifugation. The dimerization involves a domain swap of the activation loop, resulting in a different conformation of the DFG motif as compared to that seen in other kinase complexes with VX-680. The binding of INCENP differs significantly from that seen in the Xenopus laevis Aurora B:INCENP complex currently used as a model for structure-based design for this important oncology target.
Figure 1. Chemical structure
of compound 1 (VX-680).
Figure 2. Overview of human Aurora
B kinase as compared to X. laevis Aurora B and human
Aurora A. (A) Human Aurora B with INCENP colored
green and the activation loop colored red. (B) X. laevis Aurora B complex with Hesperadin (PDB ID: 2BFY),8 with INCENP
colored green and the activation loop colored red. (C) Human Aurora
A complex with 1 (PDB ID: 3E5A),13 with TPX2
colored green and the activation loop colored red.
Figure 3. Activation loop exchange of Aurora B kinase. (A) The two
Aurora
B molecules in the dimer are colored in yellow and blue, INCENP is
green, and the activation loops are colored red with dashed lines
to indicate where the disordered residues would form a connection.
Part of the activation loop packs against the αC helix. (B)
The electron density at the cross-over point for the domain swap.
The two molecules of Aurora B are colored in orange and blue. The
dashed lines in red indicate the connections that would be made between
Met249 and His250 in the absence of a domain swap. (C) As in panel
A but with one Aurora B:INCENP molecule displayed as a surface, showing
the binding of the activation loop in the dimeric arrangement. (D)
The activation loop residues involved in the binding.
Figure 4. Sedimentation velocity
analysis of AuroraB:INCENP, showing a 2D
plot of f/f0 on the Y-axis and s on the X-axis.
The smaller and larger peaks correspond to monomeric and dimeric AuroraB:INCENP,
respectively. Peak height is indicated by color on a scale from blue
to red (strongest).
Figure 5. Interface between Aurora B kinase and
INCENP. (A) Sequence alignment
of human and X. laevis INCENP over the C-terminal
IN-box region. (B) Comparison of human and X. laevis Aurora B:INCENP binding at site 1 (residues 842â863 of human
INCENP) showing the mostly conserved interactions, with two exceptions
highlighted. The X. laevis Aurora B and INCENP are
colored blue and purple, respectively (X. laevis coordinates
were taken from PDB ID 2BFX(8)). (C) Comparison of human
and X. laevis Aurora B:INCENP binding at site 2 (residues
868â881 of human INCENP) showing the mostly nonconserved binding
conformation, with the exception of the terminal Phe881. (D) Binding
detail for site 2 of human Aurora B:INCENP.
Figure 6. Comparison of binding
to 1 by Aurora B, Aurora A,
and ABL2. (A) Aurora B:1. (B) Aurora A:1 (PDB ID: 3E5A).13 (C) ABL2:1 (PDB ID: 2XYN).25 (D) Overlay of the DFG motifs of the complexes with 1 of Aurora B (in yellow) and Aurora A (in pink). (E) Overlay
of the DFG motifs of the complexes with 1 of Aurora B
(in yellow) and ABL2 (in blue).
Adams,
Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
2010, Pubmed
Adams,
Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
2010,
Pubmed
Andersen,
Discovery of selective aminothiazole aurora kinase inhibitors.
2008,
Pubmed
,
Xenbase
Anderson,
Binding of TPX2 to Aurora A alters substrate and inhibitor interactions.
2007,
Pubmed
Anderson,
Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.
2009,
Pubmed
,
Xenbase
Bayliss,
Structural basis of Aurora-A activation by TPX2 at the mitotic spindle.
2003,
Pubmed
,
Xenbase
Brown,
Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation.
2006,
Pubmed
Cheetham,
Crystal structure of aurora-2, an oncogenic serine/threonine kinase.
2002,
Pubmed
Cheetham,
Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.
2007,
Pubmed
Collaborative Computational Project, Number 4,
The CCP4 suite: programs for protein crystallography.
1994,
Pubmed
D'Alise,
Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells.
2008,
Pubmed
Emsley,
Coot: model-building tools for molecular graphics.
2004,
Pubmed
Evans,
Scaling and assessment of data quality.
2006,
Pubmed
Girdler,
Molecular basis of drug resistance in aurora kinases.
2008,
Pubmed
Harrington,
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.
2004,
Pubmed
Honda,
Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis.
2003,
Pubmed
Kabsch,
XDS.
2010,
Pubmed
Keen,
Aurora-kinase inhibitors as anticancer agents.
2004,
Pubmed
Kwiatkowski,
Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.
2012,
Pubmed
,
Xenbase
Manfredi,
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.
2007,
Pubmed
McCoy,
Phaser crystallographic software.
2007,
Pubmed
Mortlock,
Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
2007,
Pubmed
Murshudov,
Refinement of macromolecular structures by the maximum-likelihood method.
1997,
Pubmed
Nowakowski,
Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography.
2002,
Pubmed
,
Xenbase
Oliver,
Activation segment exchange: a common mechanism of kinase autophosphorylation?
2007,
Pubmed
Oliver,
Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange.
2006,
Pubmed
Petsalaki,
Phosphorylation at serine 331 is required for Aurora B activation.
2011,
Pubmed
Pike,
Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites.
2008,
Pubmed
Ruchaud,
Chromosomal passengers: conducting cell division.
2007,
Pubmed
Salah,
Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.
2011,
Pubmed
Santaguida,
Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine.
2010,
Pubmed
Savitsky,
High-throughput production of human proteins for crystallization: the SGC experience.
2010,
Pubmed
Schuck,
Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling.
2000,
Pubmed
Schuck,
Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems.
2002,
Pubmed
Sessa,
Mechanism of Aurora B activation by INCENP and inhibition by hesperadin.
2005,
Pubmed
,
Xenbase
Shimomura,
MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
2010,
Pubmed
Vader,
The Aurora kinase family in cell division and cancer.
2008,
Pubmed
Vader,
The chromosomal passenger complex: guiding Aurora-B through mitosis.
2006,
Pubmed
Young,
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
2006,
Pubmed
Zhao,
Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2.
2008,
Pubmed